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Abstract
Background: Like other steroid hormones, vitamin D elicits both transcriptional events and rapid non genomic effects.
Vitamin D receptor (VDR) localization and mechanisms of VDR-triggered non genomic responses are still controversial.
Although anticoagulant effects of vitamin D have been reported and VDR signalling has been characterized in monocytes
and vascular cells, nothing is known about VDR expression and functions in human platelets, anucleated fragments of
megakaryocytes which are known targets of other steroids.
Methodology/Principal Findings: In this study we characterized the expression and cellular localization of VDR in human
platelets and in a megakaryocyte lineage. Human platelets and their TPA-differentiated precursors expressed a classical 50
kDa VDR protein, which increased with megakaryocytes maturation. By biochemical fractionation studies we demonstrated
the presence of the receptor in the soluble and mitochondrial compartment of human platelets, and the observation was
confirmed by immunoelectron microscopy analysis. Similar localization was found in mature megakaryocytes, where
besides its classical nuclear localization the receptor was evident as soluble and mitochondria resident protein.
Conclusions: The results reported here suggest that megakaryocytopoiesis and platelet activation, which are calcium-
dependent events, might be modulated by a mitochondrial non genomic activity of VDR. These data open challenging
future studies on VDR physiological role in platelets and more generally in mitochondria.
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Introduction
The vitamin D endocrine system plays a crucial role in calcium
homeostasis and bone metabolism [1,2]. The biological effects of
1,25(OH)2D3 are mediated mainly by its interaction with the
vitamin D receptor (VDR), which belongs to the same family as
the steroid and retinoid receptors [3], via genomic and non
genomic mechanisms of action. In fact besides the classical VDR
role as transcription factor vitamin D compounds, like other
steroid hormones, can also elicit responses that are too rapid to
involve changes in gene expression and appear to be mediated by
cell surface receptors. Among the non-genomic actions of 1a,25-
dihydroxy vitamin D3 are the opening of L-type Ca2 channels in
osteoblasts which results in a rapid increase of intracellular calcium
[4]. The extranuclear receptor localization is still controversial.
Several reports indicate a subcellular distribution in the cytoplasm,
in discrete regions of the nucleus and along the nuclear envelope
[5], whereas the membrane-initiated effects are attributed to a
plasma membrane-associated receptor [6]; in fact VDR has been
found in cavolae-enriched plasma membrane [7]. Moreover
microscopy studies have revealed that VDR has mitochondrial,
membrane, cytosol and perinuclear localization [8]. During the
past two decades an increasing number of experimental data have
revealed a broad range of biological actions for VDR, that include
induction of cell differentiation [9,10], inhibition of cell growth
[11], immuno-modulation [12,13], and control of other hormonal
systems [14,15]. In addition to vitamin D classical target tissues,
VDR is also expressed in monocytic cells [16] and vascular
endothelial cells [17], suggesting potential roles of vitamin D in
antithrombotic functions. It has been demonstrated the anticoag-
ulant effects of vitamin D in terms of up-regulation of
thrombomodulin and down-regulation of coagulation tissue factor
in monocytes [16,18] and in vivo in aorta, liver and kidney [19].
While it is clear that the VDR/vitamin D system plays an
important role in maintaining normal antithrombotic homeostasis
in vivo, nothing is known about VDR expression and function in
platelets, the main players in thrombus formation. Platelets are
anucleated fragments of megacaryocytes whose maturation and
aggregation is calcium-driven and therefore potentially modulated
by a non genomic activity of VDR. The major structural features
of megakaryocytic differentiation are an increase in nuclear size
with DNA polyploidization and an increase in cytoplasmic volume
with formation of secretory granules and demarcation membranes.
Cytoplasmic fragments rich in mitochondria are then released and
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progressive expression of adhesive glycoprotein complexes impli-
cated in platelet function and by increases in Ca
2+ mobilization
and Ca
2+ influx by the Gq-coupled receptor agonists, thrombin
and thromboxane A2 [20]. The aim of this work was to evaluate
the expression of VDR in human platelets and characterize its
intracellular localization in order to suggest a physiological role of
the receptor. We found that human platelets express VDR, which
is mainly located in the mitochondrial compartment. Moreover
VDR expression is enhanced during differentiation of a megakar-
yocyte cell line, suggesting the requirement of VDR signalling in
mature platelets.
Materials and Methods
Primary Antibodies
The following antibodies against VDR were used: rabbit
polyclonal anti-VDR (C-terminus fragment) clone C-20 (sc-1008,
Santa Cruz Biotechnology, CA); rat monoclonal anti-VDR biotin-
labelled (aa 89-105 epitope) clone 9A7c.E10.E4 (RT-200-B,
LabVision NeoMarkers, CA). Polyclonal antibody against
GAPDH and monoclonal antibodies against CD34, CD41 and
CD42b were from Santa Cruz. Polyclonal antibody anti-COX-1
was from Cayman-Chemical Co, Ann Arbor, MI. Monoclonal
antibody anti-porin (31HL) was purchased from Calbiochem, La
Jolla, CA. Polyclonal antibody against Von Willebrand Factor was
obtained from Sigma.
Platelets Isolation
Peripheral blood samples were collected with written informed
consent from blood donations by healthy adult donors of both
sexes provided by the local blood bank (S. Giovanni Battista
Hospital, Turin, Italy). Samples were collected into sterile acid
citrate dextrose anticoagulant and centrifuged twice at 200 x g for
15 min; the resultant platelet-rich plasma (PRP) was used as source
of platelets. Platelets were isolated by centrifugation of PRP at
1,400 x g for 10 min, and recovered after two washes in washing
solution 1 (12.72 mM sodium citrate, 2.99 mM glucose, 9.41 mM
NaCl, 0.55 mM EDTA) and washing solution 2 (1 mM Tris-HCl,
2.99 mM glucose, 15.38 mM NaCl, 0.55 mM EDTA, pH 7.4).
Cell Culture and Flow Cytometry Analysis
The human megakaryoblastic leukaemia cell line MEG-01 was
purchased from ATCC (Rockville, MD), cultured in in RPMI-
1640 with Glutamax (Invitrogen), 10% foetal bovine serum and
1% penicillin (100 IU/ml)/streptomycin (100 mg/ml), and main-
tained in plastic dishes in a humidified atmosphere at 37uC and
5% CO2. Cells were treated for reported time with 16 nM TPA
and medium changed every four days. Indirect immunofluorescent
tests were performed by incubating 0.5x10
6 cells in suspension
with purified monoclonal antibodies (dil. 1:200 in PBS + 1% heat-
inactivated fetal bovine serum, FBS) for 30 min at 4uC. Bound
antibodies were revealed by fluorescein isothiocyanate (FITC)-
conjugated F(ab’)2 sheep anti-mouse IgG (dil. 1:200, Sigma
Aldrich, Inc., St. Louis, MO). Cells were then analyzed on a
FACScan flow cytometer (Becton Dickinson) by CellQuest
software.
Extracts Preparation, Immunoprecipitation and Western
Blotting
Platelet and MEG-01 lysates for western blotting were prepared
by a hot lysis method, carried out resuspending the samples in
boiling sample buffer 1x (SB1x: 100 mM Tris-HCl pH 6.8, 15%
glycerol, 2% SDS, and 1% protease inhibitor cocktail set III
(Calbiochem-Novabiochem Corporation, La Jolla, CA). For
immunoprecipitation studies platelets were resuspended in lysis
buffer (25 mM Hepes pH 7.4, 135 mM NaCl, 1% NP40, 5 mM
EDTA, 1 mM EGTA, 50 mM NaF, 10% glycerol and 1%
protease inhibitor cocktail set III) and incubated at 4uC for 15 min
with constant rotation. Lysates (500 mg of proteins) were then
incubated with rotation overnight at 4uC with 2 mg of rabbit
polyclonal antibody anti-VDR, followed by an additional incuba-
tion for 2 h with protein G agarose beads. Proteins were collected
by centrifugation after boiling in SB 1x. Total cell lysates (30 mg)
and immune complexes were separated by 10% SDS-PAGE and
then transferred overnight to PVDF membranes (Immobilon-P,
Millipore, Bedford, MA). Western blotting analysis was performed
as described previously [21]. Proteins were immunostained with
the indicated primary antibodies for 1 h at room temperature.
Detection of protein of interest was performed using peroxidase-
conjugated secondary antibodies (Pierce, Rockford, IL) followed by
ECL detection (ECL detection kit, Perkin Elmer Life Science,
Boston, MA, USA). Identification of VDR from immunoprecip-
itates was carried out with the biotinylated 9A7c primary antibody
followed by a streptavidin-HRP incubation. VDR bands from
protein electrophoresis were quantified by scanning digital
densitometry using an ImageJ software analysis (Sun Microsystems
Inc., Palo Alto, CA); each VDR band was normalized by detection
and densitometric analysis of a housekeeping gene (GAPDH).
Purification of Caveolae
A detergent-free method for purifying caveolae membrane was
published by Smart et al [22], and was followed with some
modifications. 100 ml of PRP were the source of a platelets pellet,
which was resuspended in hypotonic lysis buffer (10 mM Tris-
HCl, pH 7.4 and 1% protease inhibitor cocktail set III). After
incubation for 30 min on ice platelets were lysed by five passages
through an insulin syringe needle. Samples were spinned for 10
min at 1000 x g and pellets were subjected again to the same lysis
procedure. The two supernatants were combined and an aliquot
kept for protein analysis (total extract). Samples were layered on
top of 30% Percoll and centrifuged at 84,000 x g for 30 min in a
Beckman SW40 Ti rotor. The plasma membrane fraction, a
visible band at 2/3 from the bottom of the centrifuge tube, was
collected and sonicated twice on ice. An aliquot of the sonicate was
saved (plasma membrane, PM) before separating the remainder on
a linear 20% to 10% OptiPrep gradient by centrifugation at
52,000 x g for 90 min in a Beckman SW40 Ti rotor. The top 5 ml
of the gradient was collected, was overlaid with 5% OptiPrep and
centrifuged at 52,000 x g for 90 min in a Beckman SW40 Ti rotor.
A distinct opaque band present at the overlay interface was
collected and designated caveolar membranes. Proteins were
pelleted by ultracentrifugation at 100,000 x g for 60 min in a
Beckman 70.1 Ti rotor and resuspended in 50 ml of SB 1x.
Purification of Alpha Granules and Mitochondria
Subcellular fractionation was carried out following the proce-
dure described by Broekman et al [23], with some modifications.
Total extract was obtained from 350 ml of PRP as described for
caveolae purification and an aliquot kept for protein analysis. One
fifth of total extract was centrifuged at 100,000 x g for 60 min in a
Beckman 70.1 Ti rotor. Pellet was resuspended in 50 ml of sample
buffer 1x and designated total membranes, while supernatant
represented the soluble fraction of platelets. The remainder of total
extract was layered on linear 30–60% sucrose gradient and
centrifuged at 134,000 x g for 120 min in a Beckman SW40 Ti
rotor. Particulate zones were identified by their light-scattering
properties, and after harvesting were diluted three- to fivefold with
VDR in Human Platelets
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for 60 min in a Beckman 70.1 Ti rotor before resuspension in
50 ml of sample buffer 1x. A typical density gradient separation
showed two mainly visible bands, further characterized in their
mitochondria or alpha granules content by the presence of
organelles markers.
Proteinase K Treatment
Mitochondria isolated by differential centrifugation at 10,000 x
g for 10 min were treated with proteinase K (Sigma) at a final
concentration of 50 mg/ml for 25 min at 0uC. Phenylmethylsulfo-
nyl fluoride was then added to a final concentration of 2 mM, and
samples were incubated for a further 10 min at 0uC. Mitochondria
were then pelleted by centrifugation, lysed in 50 ml of SB 1x and
equal amount of proteins analysed by western blotting.
Immunoelectron Microscopy
Platelets were isolated from PRP as described in platelets isolation
section. MEG-01 cells were collected by trypsinization. Both platelets
and MEG-01 cells were prepared for immunoelectron microscopy as
previously described [24]. Briefly, after fixation samples were
incubated with polyclonal rabbit anti-VDR (200ug/ml, dil.1:20),
o v e r n i g h ta t4 uC, followed by incubation for 1 h with GAR 15 (gold
conjugated anti-rabbit antibody, 15 nm diameter, British Biocell
International, Cardiff UK). Negative controls were performed by
omitting the primary antibody. Samples were examined with a
Philips CM 10 electron microscope (Philips, Eindoven, The
Netherlands) after uranyl acetate and lead citrate staining.
Statistical Analysis
Statistical analysis of data was performed using one-way
ANOVA test with Tuckey correction. p values ,0.05 were
considered significant and indicated. All experiments were
repeated at least 3 times and quantitative data were expressed as
mean 6 S.E.M or as mean 6 S.D.
Results
Human Platelets Express VDR
Western blot analysis of whole lysate from human platelets was
performed with two antibodies raised against different regions of
the VDR protein. Both the rabbit polyclonal and the monoclonal
9A7 gamma anti-VDR showed an immunoreactive band at the
reported molecular weight of about 50 kDa [8,25], together with
several non specific bands (Figure 1, left and right lane). The
identity of the 50 kDa VDR protein was proved by immunopre-
cipitation studies, which confirmed the recognition of the same
protein by the two antibodies (Figure 1, middle lane). Immuno-
precipitation was performed using the rabbit polyclonal anti-VDR
antibody and detection was carried out with the biotinylated 9A7c
primary antibody followed by a streptavidin-HRP incubation, in
order to avoid the signal given by immunoglobulins. The
specificity of the two antibodies for different epitopes allowed the
elimination of non specific bands and showed a prominent signal
at the correct molecular weight. Further studies on VDR
expression and localization were performed using the polyclonal
antibody, which gave the clearest 50 kDa signal.
Platelet VDR Is Not a Plasma Membrane Protein and Is
Mainly Localized in the Mitochondrial Subcellular
Fraction
The anucleated platelets are a good model to study the
extranuclear VDR localization involved in the non genomic
response to vitamin D. We decided to characterize the subcellular
distribution of the receptor by biochemical protein fractionation
studies. We evaluated first its possible expression on plasma
membrane, since VDR has been found in the caveolae-enriched
membrane regions of several cells [7,26]. Plasma membranes and
caveolae fraction were isolated from whole lysate by a detergent-
free purification protocol based on gradient fractionation, and
equal amounts of proteins were analysed by western blotting. As
shown in figure 2 VDR expression, evident in whole cell lysate,
was absent in both plasma membrane and caveolae fraction. To
validate the soundness of our purification we checked the content
of two proteins known as resident in the caveolar regions of the
plasma membrane: caveolin resulted highly concentrated in
caveolar fraction and endothelial NOS was gradually enriched
Figure 1. VDR expression in human platelets extracts. 30 mgo f
proteins from whole lysates were analysed for VDR expression by
western blotting using two different antibodies. Left panel: whole lysate
was evaluated by rabbit anti-VDR antibody (anti-VDRr). Right panel:
VDR from whole lysate was detected by monoclonal biotinylated
antibody (anti-VDRb). Middle panel: lysate was immunoprecipitate with
anti-VDRr and detection by western blotting was performed with anti-
VDRb. The 50 KDa molecular weight is shown for reference.
doi:10.1371/journal.pone.0008670.g001
Figure 2. VDR expression on human platelets plasma mem-
brane and caveolae. After subcellular fractionation procedures
described in methods, 10 mg of proteins from total extracts (TOTAL),
plasma membrane fraction (PM) and caveolae fraction (CAV) were
separated by SDS-PAGE and analysed for VDR expression by western
blotting using the rabbit anti-VDR antibody (upper panel). To validate
the soundness of purification, the enrichment in two caveolae-
associated proteins was checked by detection of caveolin (middle
panel) and endothelial NOS (lower panel) with the corresponding
antibodies. Reference molecular weights are shown on left.
doi:10.1371/journal.pone.0008670.g002
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caveolae.
We next checked whether platelet VDR was a soluble
cytoplasmic protein or associated with the mitochondrial com-
partment, particularly abundant in platelets. The latter subcellular
localization was suggested by recent works which found the
receptor in the mitochondria of rat intestinal cells [8]. Proteins
from whole lysate were subjected to ultracentrifugation to obtain a
particulate fraction comprehensive of all proteins associated to
membranes or vesicles and a soluble fraction containing the
cytoplasmatic proteins. Protein analysis of the soluble and
particulate fraction (Figure 3) revealed a VDR both soluble and
membrane associated. Moreover from the whole lysate upon
density gradient centrifugation we purified a fraction highly
enriched in mitochondria and a fraction mainly composed by
alpha granules. We analysed VDR expression in all fractions by
western blotting and we assessed the content of all fractions in
terms of porin as mitochondrial marker and Von Willebrand
Factor (VWF) as protein associated to alpha granules. As described
in methods and showed in Figure 3, we obtained a fraction 1
mainly composed by alpha granules (VWF positive and scarce
porin content) which did not show VDR expression. From the
same purification procedure we extracted a fraction 2 mainly
mitochondrial in nature (porin positive with minor content of
VWF, a contamination found also in the soluble fraction) which
was highly enriched in VDR. From this biochemical study we
could conclude that platelet VDR is substantially associated with
the mitochondrial compartment.
VDR Is Stored in Mitochondria of Human Platelets
Immunoelectron microscopy of platelets was performed to
confirm the conclusions drawn from the biochemical fractionation
studies. As shown in figure 4A, platelet structures were well
preserved after immunogold labeling procedures. In agreement
with the intracellular distribution suggested by western blotting
analysis, the anti-VDR antibody revealed the presence of the
receptor in the mitochondrial structures and in the cytosol,
without significant labeling of other platelet structures (Figure 4B).
VDR Expression Increases during Megakaryocyte
Differentiation
Platelets are derived from megakaryocytes resident in the bone
marrow. During megakaryocyte maturation, the polyploid cell
undergoes a complex process of cytoskeletal rearrangement,
followed by proplatelet elongation, and the release of cytoplasmic
fragments as circulating platelets [27]. Since platelets are
anucleated and contain only a trivial amount of mRNA, they
lack significant capacity for protein synthesis and regulation of
vitamin D receptor protein expression must occur during
megakaryocytopoiesis or thrombopoiesis. It has been reported
that VDR mRNA is expressed in megakaryoblastic cells and the
treatment with forskolin, a differentiating drug activator of
adenylate cyclase, causes an increase in VDR mRNA levels
Figure 3. VDR distribution in soluble and mitochondrial
fractions of human platelets. Following density gradient purifica-
tion and ultracentrifugation as described in methods, subcellular
fractions were obtained and 30 mg of each sample was analysed by
western blotting. VDR rabbit antibody detected a 50 KDa band in total
extract (total), cytosolic fraction (soluble) and total membranes
preparation (membranes). VDR expression was enriched in fraction 2
(mitochondrial) while was absent in fraction 1. To assess the
composition of fractions, the detection of a mitochondrial protein
(porin) and an alpha-granules associated protein (Von Willebrand Factor
VWF) was performed. Porin resulted enriched in membranes fraction
and markedly in mitochondrial fraction 1, while VWF was mainly found
in fraction 1. Reference molecular weights are shown on left.
doi:10.1371/journal.pone.0008670.g003
Figure 4. The VDR storage site in human platelets. (A) Platelets
observation by electron microscopy revealed a well preserved cell
structure and organization of intracellular granules. Sample was
processed in absence of anti-VDR primary antibody. (B) Immunogold
labelling of VDR in human platelets, showing occasional VDR labelling
in mitochondria (M) and cytosol, with no significant labelling of alpha
granules (A), or plasma membrane. Inset shows a mitochondrial
structure under higher magnification. Experiments were performed as
outlined in Immunoelectron microscopy section.
doi:10.1371/journal.pone.0008670.g004
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process, we analysed receptor expression in MEG-01 cells, a
human megakaryoblastic leukaemia cell line which maintains
some characteristics of megakaryocytes. Differentiation was
triggered in vitro by the phorbolester 12-O-tetradecanoylphor-
bol-13-acetate (TPA), a stimulator of protein kinase C known to
induce megakaryocytic maturation as demonstrated by enlarge-
ment of cell size, multiplication of nuclei, increase in granularity
and in expression of platelet-specific proteins [29,30]. MEG-01
cells were treated for eight days with 16 nM TPA and then their
differentiated state was characterized in terms of morphological
changes and protein pattern expression. A prominent response to
TPA treatment was demonstrated as shown in figure 5: the cells
became weakly adherent and displayed mature megakaryocytic
characteristics by electron microscopy such as the development of
cytoplasmic blebs and a multiplication of nuclei (figure 5B). MEG-
01 cells were periodically harvested during incubation in absence
(control: C0, C4 and C8) and in presence of TPA (T4 and T8).
The most used surface antigens markers of early myeloid (CD34)
and mature megakaryocyte stage (CD41, CD42b) [31,32] were
evaluated by flow cytometry analysis. Moreover we quantified by
western blotting the expression of the enzyme COX-1, since it has
been reported that it increases consistently over the full course of
MEG-01 differentiation [33]. The results of our evaluation of
TPA-induced differentiated state of MEG-01 are summarized in
table 1. We observed a decrease of CD34 antigen and an increase
of CD41 and CD42 antigen expression during differentiation
(fourth day, T4) and even more at the end of eight days of TPA
treatment (T8). Similarly, COX-1 content of differentiated MEG-
01 consistently increased. Untreated cells did not show any
variation in the content of all markers (C4 and C8). TPA-treated
MEG-01 cells represent therefore an attractive model to study the
expression of VDR during differentiation of megakaryocytes. Such
expression was evaluated by western blotting in the same
experimental conditions. The 50 kDa VDR band was quantified
and results expressed in arbitrary density units were plotted on
graph as shown in figure 6. Interestingly, VDR content was
enhanced along the differentiation process; in fact the receptor,
fairly expressed in control cells (C0), was more abundant after four
days of treatment (T4) and at the end of the maturation process
(T8), whereas untreated cells did not show a significant increase of
VDR over the same period of incubation (C8).
Figure 5. Morphological changes of MEG-01 cells after TPA-
promoted differentiation. (A) Electron microscopic photograph of
control MEG-0l cells. The round nucleus and the relatively developed
cytosol with homogeneous organization can be observed. (B) Electron
microscopic photograph of MEG-0l cells treated for eight days with 16
nM TPA. Peripherally located and multiple nuclei are evident. Prominent
cytoplasmic blebs are observed.
doi:10.1371/journal.pone.0008670.g005
Figure 6. VDR expression during megakaryocyte maturation
triggered by TPA. MEG-01 cells were incubated in absence or
presence of 16 nM TPA and harvested at the indicated times. 50 mgo f
total lysate were analysed by western blotting using the rabbit anti-VDR
antibody and an anti-GAPDH antibody. VDR bands from four
independent experiments were quantified, normalized for loading as
a ratio to GAPDH expression and data plotted on graph as arbitrary
density units. Data represent the mean 6 S.E.M. *p,0.05 compared to
control at time zero.
doi:10.1371/journal.pone.0008670.g006
Table 1. Analysis of megakaryocyte maturation markers.
CD34 CD41 CD42 COX-1
C0 12,7360,257 1,1560,043 1,0360,03 0,1260,009
C4 11,0962,054 1,2360,147 1,0360,036 0,1260,022
C8 9,3561,058 * 1,4860,342 1,0660,154 0,1660,03
T4 2,9561,749 ** u 2,3160,856 * u 1,8960,112 * u 0,5960,031 * u
T8 2,6961,749 **ˆ 3,0260,58 **ˆ 2,4160,742 **ˆ 0,6960,037 *ˆ 1
*:p ,0,05 vs C0; *: p,0,05 vs C0; *: p,0,05 vs C0; *: p,0,0001 vs C0.
**:p ,0,0001 vs C0; **: p,0,001 vs C0; **: p,0,0001 vs C0; u:p ,0,0001 vs C4.
u:p ,0,0001 vs C4; u:p ,0,05 vs C4; u:p ,0,05 vs C4;ˆ: p,0,0001 vs C8.
ˆ :p ,0,0001 vs C8; ˆ: p,0,01 vs C8; ˆ: p,0,0001 vs C8; 1:p ,0,001 vs T4.
MEG-01 cells were analysed for their maturation stage after four (T4) and eight
(T8) days of treatment with 16 nM TPA and compared with control cells at the
same incubation time (C0, C4, C8). Markers of early myeloid (CD34) and mature
megakaryocyte stage (CD41, CD42b) were evaluated by flow cytometry
analysis, whereas the expression of COX-1 was assessed by western blotting
analysis and quantification of immunoreactive bands normalized as a ratio to
GAPDH expression. Data from three independent experiments were used and
are shown as mean 6 S.D. Significance of data referred to treated vs control
cells is indicated at the bottom.
doi:10.1371/journal.pone.0008670.t001
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and Mitochondrial Compartments
The same immunoelectron microscopy analysis performed on
platelets was carried out on MEG-01 cells. As shown in figure 7A
untreated cell were positive for VDR labeling and displayed a
receptor expressed in the nuclear region, cytosol and most
interestingly in mitochondrial organelles. The same pattern was
evident in TPA-differentiated cells, with a more evident presence
in mitochondria (figure 7B). Microscopy observations confirm
therefore the data collected by protein analysis, and reveal a
mitochondrial localization of VDR even in megakaryocytes, the
platelets precursor cells. Even though the microscopy images
clearly showed a VDR localized in the inner compartment of
mitochondria, in order to definitely exclude that the receptor is
attached to organelles and not incorporated, a treatment with
proteinase K was performed on mitochondrial extracts. The levels
of VDR and cytochrome C, another internal mitochondrial
protein, were not significantly affected by the treatment, as shown
in figure 7C.
Discussion
In this work we report for the first time not only the presence of
VDR in human platelets but also most interestingly its
mitochondrial localization. Like for other tissues, non genomic
effects of VDR have been documented in vascular and blood cells
too. The most known rapid non genomic effects of vitamin D are
associated to the control of intracellular calcium levels. In fact
1,25(OH)2D3 can rapidly stimulate phosphoinositide metabolism,
cytosolic calcium levels, cGMP levels, PKC, MAP kinases, and the
opening of chloride channels (reviewed in [34]). In human
peripheral blood mononuclear cells vitamin D is capable of
exerting a rapid non genomic effect on intracellular calcium
concentration [35]. 1,25(OH)2D3 induces vascular smooth muscle
cell (VSMC) migration independent of gene transcription via PI3
kinase pathway [36]. Up to now nothing was known about VDR
expression in platelets. The idea that these anucleated cells are
responsive to the obviously non genomic effects of steroids is not
new. Several evidences indicate that sex hormones affect platelet
physiology, and it has been reported the expression of estrogen
receptor (ER) beta and androgen receptor (AR) in human platelets
[37]. Moreover it has been described the existence of glucocor-
ticoid receptor (GR)/mineralcorticoid receptor (MR) heterodimers
in platelets [38]. Our work demonstrates the presence of a classical
form of VDR in human platelets. When we sought to investigate
its subcellular distribution, we hypothesized a similarity with ER
beta localization in caveolar structures of platelets plasmamem-
brane, a binding which has been demonstrated important for its
intracellular signalling [39]. Several findings support the notion
that rapid estrogen signaling is mediated by ER associated with
specialized lipid raft domains that serve to concentrate and
provide a matrix for receptors and related signaling proteins
[40,41]. However, by a purification procedure based on gradient
centrifugation we discovered that platelets plasma membrane and
caveolar fraction resulted devoid of the receptor. A soluble protein
was hence expected, since the cytosolic localization has been
reported for ER beta and AR in platelets [37]; nevertheless a
possible alternative was suggested by a recent work of Gonzalez-
Pardo and coll., who described a mitochondrial VDR [8]. Indeed,
fractionation studies demonstrated the presence of the receptor in
the mitochondrial compartment, and the observation was
confirmed by immunoelectron microscopy analysis of platelets.
These data open challenging future studies on VDR physiological
role in platelets and more generally in mitochondria. Further
investigations are needed in order to understand the mechanisms
of VDR mitochondrial import and its function in these organelles.
The intracellular distribution of VDR is dependent not only on
subcellular localization signals encoded in the protein but also on
the nature and composition of the multi-molecular complexes
formed by the receptor. A mitochondrial localization signal has
not been described yet for VDR protein, however future analysis
could show a putative internal mitochondrial targeting polypeptide
signal (mtTPs) similarly to the one identified in human ERb [42]
and in glucocorticoid receptor [43], which are localized in
mitochondria. Alternatively VDR association with other molecules
could facilitate its translocation. It has been shown that post-
translational events substantially alter RXRa location by address-
Figure 7. VDR distribution in intracellular compartments of
MEG-01 cells. (A) Electron micrograph of control MEG-0l cells reacted
with rabbit anti-VDR antibody. Nuclear space (N), cytosol and
mitochondria are positive for VDR. (B) Electron micrograph of MEG-01
cells treated for eight days with 16 nM TPA reacted with anti-VDR
antibody. Mitochondria and cytosolic areas are positive for VDR.
Cytoplasmic blebs are evident (closed arrowheads). (C) Treatment of
mitochondria from MEG-01 cells with proteinase K. Proteins from
mitochondria untreated (control, C) or treated with proteinase K (P)
were analysed by western blotting using antibodies against VDR and
cytochrome C.
doi:10.1371/journal.pone.0008670.g007
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DNA by forming heterodimerical complexes with p43, a truncated
version of the triiodothyronine nuclear receptor [44]. Since RXR
is a VDR binding partner one could reasonably postulate a
heterodimeric RXR/VDR mitochondrial translocation and tran-
scriptional activity. Besides the transcriptional control of mito-
chondrial genes steroid hormones may influence mitochondrial
function by non genomic interactions that may control mitochon-
drial cation fluxes (reviewed in [45]). These actions regulate major
mitochondrial functions including mitochondrial-dependent apo-
ptosis and the same role could be played by VDR in platelets.
Because platelets are anucleated, their protein content is a
consequence of gene expression in precursor cells known as
megakaryocytes. We used the immortalized human megakaryo-
blastic cell line MEG-01 as a model to study the expression and
localization of VDR in platelets progenitors, since MEG-01 cells
can be induced to differentiate into platelet-like structures by
adding nanomolar concentrations of 12-0-tetradecanoylphorbol-
13-acetate (TPA). In our study MEG-01 cells were able to
differentiate morphologically and biochemically into more mature
megakaryocytes and platelet-like structures after stimulation with
phorbol esters and, therefore, represent an attractive model to
study the modulation of VDR expression during differentiation of
megakaryocytes. As reasonably expected, VDR expression and
localization found in human platelets was matched by the presence
of the receptor in precursor cells, a presence which is reinforced
during a differentiation process which preludes to platelets
formation. Likewise platelets analysis, to our knowledge this is
the first report characterizing VDR expression and localization in
megakaryocytes. It has been described the expression of other
steroid hormone receptors in human megakaryocytes and their
increase during differentiation [37]. On the other hand few
published data demonstrate that the megakaryocyte differentiation
process can be triggered by estrogens, vitamin D, and glucocor-
ticoids [28,46,47]. The differentiative properties of vitamin D are
augmented by forskolin, an activator of adenylate cyclase and
modulator of cell proliferation and differentiation [28]. These
observations suggest that 1,25(OH)2D3 might play an important
role in megakaryocytopoiesis or at least potentiate the effect of
other antiproliferative stimuli.
The role of VDR in progenitors differentiation and mature
platelets remains to be elucidated. The control of calcium
homeostasis is the most probable nongenomic function of platelet
VDR, given the important role of calcium fluxes in platelets
formation, aggregation and granule content release. This possi-
bility is supported by observations on nongenomic effects of sex
hormones in platelets [48], such as the fact that in vitro
testosterone appears to enhance platelet aggregation [37]. As
modulator of calcium fluxes VDR could play an essential role in
megakaryocytopoiesis, platelets activation and apoptosis, which
are calcium-dependent events [20,49].
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